Chordoid glioma: a rare radiologically, histologically, and clinically mystifying lesion by unknown
WORLD JOURNAL OF 
SURGICAL ONCOLOGY
Bongetta et al. World Journal of Surgical Oncology  (2015) 13:188 
DOI 10.1186/s12957-015-0603-9CASE REPORT Open AccessChordoid glioma: a rare radiologically,
histologically, and clinically mystifying lesion
Daniele Bongetta1*, Andrea Risso1, Patrizia Morbini2, Giorgio Butti3 and Paolo Gaetani3Abstract
Chordoid glioma (CG) is a rare central nervous system neoplasm (WHO grade II) of uncertain origin whose typical
localization is in the anterior part of the third ventricle. Its clinical, radiological, and histological features may vary
and furthermore mimic other kind of benign lesions usually associated with a better outcome. We report a case of
a 43-year-old female who underwent gross total removal of a lesion of the third ventricle causing hydrocephalus.
The imaging studies and the intraoperative examination led at first to a hypothesis of meningioma. Early surgical and
neurological outcomes were good. The patient underwent multiple complications related to hypothalamic dysfunctions
and thrombohemorragic issues and eventually died because of systemic infections. Definitive examination was of
chordoid glioma of the third ventricle. Reviewing literature, we evaluated possible pitfalls in radiological and histological
diagnosis as well as in surgical and medical treatment of CGs. Despite their benign presentation, a high incidence of
multiple possible severe complications is reported. Early alertness and combined treatment strategies could improve
overall CGs treatment strategies.
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Chordoid glioma is a rare glial neoplasm firstly labeled as
a new pathologic entity by Brat et al. in 1998 [1], although
Wanschitz et al. described its features as a meningioma
variant in 1995 [2]. World Health Organization 2007 clas-
sification assigned it a grade II [3]. It usually occurs in
adults (mean age, 46) with a female predominance of 2:1;
only three pediatric cases are reported in literature [4–6].
Clinical presentation is usually with headache, visual dis-
turbances, and memory deficits [7]; less frequent presenta-
tion is with hypothalamic and/or hypophysis disturbances
(amenorrhea, hypothyroidism, weight gain, polydipsia) [8];
other focal deficits are rare. Its localization is usually in
the anterior part of the third ventricle with variable exten-
sion to the suprasellar region and lateral ventricles; hydro-
cephalus is present in nearly 1/4 of patients depending
more on tumor location rather than size [9]. Radiological
findings usually show a well-circumscribed ovoid lesion
hyperattenuating at computed tomography (CT) scans and
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creativecommons.org/publicdomain/zero/1.0/magnetic resonance imaging (MRI) scans. Contrast en-
hancement is vivid; there may be cystic changes and rare
calcifications [10–12]. Chordoid glioma histologic features
show clusters and cords of epithelioid cells with eosinophilic
cytoplasm embedded in a mucinous matrix rich in lympho-
plasmacellular infiltrates and Russell bodies; mitotic activity,
vascular proliferation, nuclear atypia, and necrosis are rare
or absent [13, 14]. Immunohistochemical analysis is charac-
terized by strong and diffuse reaction to glial fibrillary acidic
protein (GFAP) and Vimentin; epithelial membrane antigen
(EMA), CD34, S-100, and cytokeratin are expressed in more
than 2/3 of samples [15]. Neurofilament protein, synapto-
physin, and p53 are rarely positive; MIB-1 index is always
lower than 5 %. The general hypothesis of the chordoid gli-
oma histogenesis favors a glial origin, especially from the
ependymal cells called tanycytes [16], located in the anterior
part of the third ventricle; a hypothesis of a multipotent
stem cell of Rathke’s pouch [17] or even ependymal origin
have been reported [18]. As has been recently reported,
thyroid-transcription factor-1 expression may histogeneti-
cally link these lesions to other morphologically heteroge-
neous neoplasms in the third ventricular region [19]. We
report a case with a perioperative satisfactory result, whosearticle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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cidence of possible threatening complications.
Case presentation
We present a case of a 43-year-old woman, with a 6-year
history of diabetes mellitus. In the last few weeks preceding
her hospitalization she suffered from headache, asthenia,
and mood depression; since her headache kept worsening,
she was eventually admitted to our Hospital. Neurological
examination showed no significant deficit, electroenceph-
alogram (EEG) was normal, fundus oculi study showed an
embossed, blurred papilla with peripapillary hemorrhage in
the right eye, slightly blurred margins of the left eye papilla.
She underwent a CT scan which showed a 4 × 3 × 3 cm le-
sion in the medial mesencephalic region with heteroge-
neous density with hyperdense peripheral ring and vivid
heterogeneous contrast enhancement causing noncommu-
nicating hydrocephalus. Neither edema, nor calcifications
nor cysts were noted. A hypothesis of a neoplasm with a III
ventricle origin was made. A MRI scan showed a lesion
slightly T1-hypointense, T2-heterogeneally hyperintense
with vivid heterogeneous contrast enhancement involving
little necrosis areas, cranially dislocating the fornix, minim-
ally proceeding into the lateral ventricles through the for-
amina of Monro, and anteriorly dislocating the lamina
terminalis. A millimetric heterogeneous T1-hyperintense
and GE-hypointense oval area resembling a calcification ofFig. 1 Radiological evaluation. Left: T1-weighted MRI scan showing a lesion
enhancement. Center: early postoperative CT scan showing gross total remthe lesion margin was noted near the right cerebral ped-
uncle (Fig. 1). A hypothesis of a III ventricle neoplasm ori-
ginating from choroidal plexus versus intraventricular
meningioma versus ependymoma was made. An external
ventricular drain (EVD) was placed with relief of the head-
ache, and she subsequently underwent gross total removal
of the lesion via a right pterional approach. No major com-
plications occurred during surgery, and the patient was ad-
mitted to the Intensive Care Unit for a controlled slow
awakening. Neurological examination showed no significa-
tive deficit, intracranial pressure (ICP) never went above 20
mmHg. In the early days she presented tendency to hyper-
natremia, with hyperosmotic urine output. After the onset
of fever due to Escherichia Coli urinary infection she be-
came drowsy. A CT scan showed no anomalies. Hormonal
routine revealed diminished thyroid-stimulating hormone
(TSH) levels (0.142 mIU/L; 0.400–4.000). She presented a
single partial seizure (EEG normal) after which she reverted
to hyponatremia (128 mEq/l). At the end of the first week
post intervention, she developed deep vein thrombosis in
the right popliteal district. Therapeutic low molecular
weight heparin therapy was administered; no indication of
inferior vena cava filter placement was posed. The patient
remained drowsy and once again presented tendency to
hypernatremia. A MRI scan 20 days post-op was performed
showing gross total removal of the tumor, heterogeneous
density in the surgical field, small subacute ischemic lesionsin the medial mesencephalic region with heterogeneous contrast
oval
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suffered from an acute onset of dyspnea and desaturation,
so she underwent a chest CT scan showing bilateral pul-
monary thickening in absence of frank signs of pulmonary
embolism. The respiratory functions further worsened: a
bronchoscopy with sampling isolated Candida Albicans and
Staphylococcus Aureus, a percutaneous tracheostomy was
performed. Respiratory and neurologic functions improved.
Owing to a persistent dilatation of the ventricles, she under-
went a ventricular-peritoneal shunt intervention. Postopera-
tive course was complicated by intraventricular hemorrhage
and subsequent shunt occlusion (Fig. 1). The shunting was
thus reverted to external with slow, progressive, neurological
improvement. A new septic state with isolation of Pseudo-
monas Aeruginosa and Klebsiella Pneumoniae multidrug re-
sistance (MDR) was treated with intense antimicrobial
therapy. Neurological examination showed order execution
with mild right side hemiplegia. She suffered again from
dyspnea and progressive desaturation so she underwent a
chest CT scan showing massive acute respiratory distress
syndrome (ARDS) secondary to P. Aeruginosa and K. Pneu-
moniae MDR pneumonia which eventually led her to death
about 3 months after admission.
Histology
Intraoperative examination showed fragments consisting of
edematous stroma, including aggregates of medium size
cells with eosinophilic cytoplasm and slight nuclear pleo-
morphism, with no mitotic activity, nor necrosis. A
provisional diagnosis of meningioma was made. The exam-
ination of formalin-fixed and paraffin-embedded samples
documented a neoplastic proliferation of epithelioid ele-
ments with regular nuclei, without prominent nucleoli, ar-
ranged in small nests and chains immersed in abundant
myxoid stroma. A consistent lymphoplasmacytic inflamma-
tory infiltrate was associated, no mitosis was detected; MIB-
1 proliferative index was of about 3 %. The neoplastic ele-
ments were intensely immunoreactive for Vimentin and
GFAP and moderately to S-100. No immunoreactivity for
cytokeratin, EMA, or progesterone receptor was observed.
Chordoid meningioma, chordoma, and chordaoid glioma of
the third ventricle were considered in the differential diag-
nosis. The absence of both a typical meningothelial prolifer-
ation and EMA and progesterone receptor expression
allowed us to discard the hypothesis of chordoid meningi-
oma. The diagnosis of Chordoma was considered unlikely
on account of the immunohistochemical profile and neo-
plastic cells morphology. The location of the lesion as well
as its histological characteristics and antigenic pattern led to
a diagnosis of chordoid glioma of the third ventricle (Fig. 2).
Discussion
Chordoid glioma is a rare central nervous system neo-
plasm whose determination as a distinct histological entityis relatively recent. Perioperative identification of the le-
sion with radiological and histological intraoperative ex-
aminations may be difficult, even by the most experienced
diagnosticians. On the radiological side, common misdiag-
nosis may be avoided by a differential diagnostic approach
based both on the typical localization of the lesion and the
peculiar pattern of its growth. As a matter of fact, chor-
doid gliomas typically show a rather common benign con-
trast enhancement pattern. Different MRI sequences do
not show lesion-specific characteristics; hypothesis of dif-
ferent frequent low grade neoplasm may be wrongly
made. In particular, meningiomas are more commonly re-
lated to a skull base dural feeding, and their growth pat-
tern is typically oriented to the sellar region. Moreover,
ependimomas and furthermost choroidal plexus neo-
plasms are rarely located in the anterior midline. Ectopic
pituitary adenomas are anecdotal. We agree with Smith
et al. in stating that location, age, gender, and underlying
conditions may help narrow the differential diagnosis [12].
A widespread knowledge of this newly defined third ven-
tricle pathological entity in the radiologists’ community
appears to be mandatory. As for histological examination,
recent publications report that intraoperative smear cy-
tology could reveal distinctive cytological features, identi-
fying the unique histological pattern of chordoid gliomas
[14, 20]. In literature, we found that the main problem lied
in telling a chordoid glioma from a chordoid meningioma.
As for the radiological issues, a topographic approach
could favor a correct diagnosis as early as at an intraopera-
tive analysis stage. Postoperative outcome may widely vary
from a no-deficit patient to a relatively high death rate in
the first month. Surgical interventions are often reported
as relatively easy and uneventful, suggesting that many
variables and small details are to be taken into account in
the outcome analysis. Recent reviews show a postoperative
mortality up to 17 % while deaths related to pulmonary
embolism and infectious diseases account for 45 and 36
%, respectively [21]. Diabetes insipidus and hypothalamic
disorders are common complications too. The series of
events that led to death in the case presented here may
suggest that many factors may cooperate in breaking the
fragile postoperative systemic equilibrium of these pa-
tients. In particular, we stress the possible combined role
of multiple thrombotic risk factors: the hypothalamic dis-
orders, the neurological deficits with prolonged sedation
and ICU stays, and the histology of the glial series. The
overall risk of deep vein thrombosis and related pulmon-
ary embolism may be underestimated. We thus recom-
mend an effective, timely antithrombotic prophylaxis.
Hydrocephalus treatment must also be carefully planned
considering the anticoagulation therapies. On a pure sur-
gical level, chordoid glioma management has been de-
scribed as a mere biopsy in only seven patients [8, 9, 15,
16, 22, 23]. The surgical approaches employed to access
Fig. 2 Histological evaluation. Paraffin-embedded samples of chordoid glioma documenting: a No immunoreactivity for EMA; b Epithelioid
elements with regular nuclei arranged in small nests and chains immersed in abundant myxoid stroma (H-E x 10); c (H-E x 20); d GFAP
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in transventricular (transcortical or transcallosal) and trans-
lamina terminalis (pterional or subfrontal route), whereas
transsphenoidal sublabial was employed only once [17].
Ventricular shunting is performed as needed. No recur-
rence occurred after gross total removal, while 5 recur-
rences out of 18 available partial removal cases were
reported [1, 24, 25]. Still, morbidity and mortality data pro-
gressively increase from 0 % of biopsy cases up to about 70
and 30 % in GTR cases. In our case, we chose a right pter-
ional approach with extensive basal temporal bone drilling
and performed a GTR. We evaluated that this approach
could warrant an adequate exposure of the chiasmal region
with a less invasive parenchymal approach compared to the
transventricular and lesser frontal brain retraction com-
pared to the subfrontal route. Literature data may suggest
that the trans-lamina terminalis approach is better in terms
of morbidity and mortality [21]. The choice of a surgical
route may be mainly due to the presence of objective vari-
ables such as ventricular extension and laterality and also
to the subjective surgeon’s expertise and confidence. Even
the intraoperative diagnosis plays a role in determining the
extension of the resection. The typical misdiagnosis of
meningioma at smear analysis, as in our case, could favor a
more exhaustive removal approach. There are also reports
of several other adjuvant therapies such as conventional
radiotherapy, stereotactic radiosurgery, intratumoral radio-
therapy, and Gamma Knife Surgery [1, 15, 23, 24, 26–29];
no chemotherapy treatment is reported. The knowledge ofthese promising tools for a combined treatment approach
to these lesions could modify the surgical strategy.
Conclusions
Since most physicians have little knowledge of this relative
new central nervous system tumor entity, as we had our-
selves before this case study, chordoid glioma may repre-
sent a mystifying lesion in radiological, histological, and
clinical terms. Extensive knowledge of diagnostic pitfalls
and high incidence of multiple possible severe complica-
tions could improve the outcome of chordoid gliomas
(CGs) patients. Further studies are needed to assess the cor-
rect treatment strategies in terms of complication preven-
tion, surgical approach, and role of adjuvant therapy.
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